- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
- 10-K Annual report
- 10.33 Promissory Note and Pledge Agreement
- 10.34 Amendment to Employment Agreement - David E Riggs
- 10.35 Termination Letter - Dorit Arad
- 10.36 Termination Letter - Joan Gillett
- 10.37 Separation from Employment Letter - Arthur Bollon
- 23.1 Consent of Bdo Seidman, LLP
- 23.2 Consent of Ernst & Young LLP
- 31.1 Certification of CEO Pursuant to Section 302
- 31.2 Certification of CFO Pursuant to Section 302
- 32.1 Certification of CEO Pursuant to Section 906
- 32.2 Certification of CFO Pursuant to Section 906
Exhibit 23.2
CONSENT OF INDEPENDENT AUDITORS
We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-59490) pertaining to the 2000 Stock Option Plan of eXegenics Inc., formerly Cytoclonal Pharmaceutics, Inc., the Registration Statement (Form S-8 No. 333-11691) pertaining to the 1996 Stock Option Plan of eXegenics Inc., the Registration Statement (Form S-8 No. 333-86201) pertaining to the 1996 Stock Option Plan of eXegenics Inc., the Registration Statement (Form S-8 No. 333-37049) pertaining to the 1992 Stock Option Plan of eXegenics Inc., the Registration Statement (Form S-3 No. 333-66003), the Registration Statement (Form S-3 No. 333-33838) and the Registration Statement (Form SB-2 No. 333-91802) and related prospectuses of our report dated February 28, 2003, with respect to the 2002 and 2001 financial statements of eXegenics Inc. included in the Annual Report (Form 10-K) for the year ended December 31, 2003.
ERNST & YOUNG LLP
Dallas, Texas
March 31, 2004